1  10 patients treated for onchocerciasis with diethylcarbamazine.

2 e dose of a triple-drug regimen (ivermectin, diethylcarbamazine, and albendazole) has been shown to c

3 is, topical application of the anthelminthic diethylcarbamazine (DEC) induces clinical and histologic

4             Treatment of onchocerciasis with diethylcarbamazine (DEC) or ivermectin is associated wit

5 riple-drug therapy of the antifilarial drugs diethylcarbamazine (DEC), ivermectin (IVM), and albendaz

6 s with Loa loa infection treated with either diethylcarbamazine (DEC), the drug of choice for loiasis

7                                              Diethylcarbamazine (DEC)-medicated salt may overcome the

8 before and after administration of 300 mg of diethylcarbamazine (DEC).

9 ian patients before and after treatment with diethylcarbamazine for Brugia malayi infection, and reco

10            Drugs to treat filariasis include diethylcarbamazine, ivermectin, and albendazole, which a

11  lipoxygenase inhibition was performed using diethylcarbamazine or the 5-lipoxygenase activating-prot

12                             Albendazole plus diethylcarbamazine significantly reduced prevalence of e

13 s and declined (but did not disappear) after diethylcarbamazine therapy in infected patients.

14  was positive for Wolbachia DNA 4-48 h after diethylcarbamazine treatment.